v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
In addition to the significant expense categories included within consolidated net loss presented on the Company's Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses which are presented to the Company's CODM for review:

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
External clinical development expenses (1)
SBI-100
$— $— $— $2,241 
nimacimab
1,712,59911,723,4027,041,83716,623,528
Total External clinical development expenses
1,712,59911,723,4027,041,83716,625,769
Personnel related and stock-based compensation
1,644,3151,408,0243,357,1132,745,773
Other research and development expenses (2)
585,0181,206,3271,478,6622,163,468
Total research and development expenses
$3,941,932 $14,337,753 $11,877,612 $21,535,010 
(1) External clinical development expenses include expenses for clinical trial costs and clinical manufacturing.
(2) Other research and development expenses include expenses for travel and entertainment, consulting and advisory, discovery research and development, and general business expenses.